DNMT1 and ovarian carcinoma: Preclinical studies indicated that de-methylation agents were able to reverse resistance of ovarian cancer cells to platinum [27], [28], leading to using DNMT inhibitors in clinical trials of ovarian cancers [29], [30], [31], [32].